Protagonist Therapeutics price to free cash flow PTGX

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Oct 23, 2026: 68.6×
9-year median: 52.9×
Against its 9-year history: 59th; percentile: 0 is its lowest day, 100 its highest
9-year range: 7.9× to 152×
Peer median: 46.0×

Protagonist Therapeutics' price to free cash flow is 68.6× as of Oct 23, 2026.

That is above its 9-year median of 52.9×, close to the middle of its last 9 years.

Over that time it ranged from 7.9× in May 2025 to 152× in Mar 2018.

The median for 10 large drugmakers of a similar size is 46.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	68.6×	63.8×	121×
2025	87.1×	7.9×	146×
2024	10.1×	9.9×	12.1×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	56.1×	46.6×	152×
2017	55.5×	45.5×	55.5×

Against its peers

Companies in Drug Manufacturers - General nearest Protagonist Therapeutics' size, closest first, today.

Company	Price to free cash flow
PTGXProtagonist Therapeutics	68.6×
CORTCorcept Therapeutics	86.8×
TGTXTG Therapeutics	477×
BMRNBiomarin Pharmaceutical	14.7×
ALKSAlkermes plc.	33.0×
AMRXAmneal Pharmaceuticals	50.9×
LGNDLigand Pharmaceuticals	46.0×
KNSAKiniksa Pharmaceuticals International	32.7×
JAZZJazz Pharmaceuticals	8.7×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	100×
Peer median	46.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Protagonist Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.